Dear all,
The Geuvadis RNAseq Nature paper has been scheduled for advance online 
publication on September 15 at 1800 London time, 1900 CET, which is the 
time the embargo is lifted.
A couple of points about the media strategy:
- The international press release: we're coordinating this together with 
UNIGE and EBI/EMBL press offices
- Local press releases: those of you who are planning to send out a 
local PR, please make sure that: 1) your press office receives the 
instructions from the Nature press office (copypasted below) and the 
embargo is respected, 2) your press release is distributed only 
nationally, and 3) you send a copy of your press release to me, Manolis 
and Gabrielle.
- Social media: after the embargo is lifted, you're free (and 
encouraged) to advertise the paper on twitter, facebook, your 
website/blog, etc. On twitter, please use hashtag #geuvadis; I'll be 
posting under @tuuliel.
- If you come across any substantial criticism or questions regarding 
the paper in the blogosphere or elsewhere, please let me and Manolis 
know so that we can formulate a response together.
best regards,
Tuuli
Your paper 'Transcriptome and genome sequencing uncovers functional 
variation in humans' has been *scheduled for Advance Online Publication 
(AOP) on 
http://www.nature.com/nature <http://www.nature.com/nature> on 
15 September 2013 at 1800 London time / 1300 US Eastern Time*. The 
embargo will lift at this time. Please forward this information to any 
co-authors.
Papers published online before they have been allocated to a print issue 
will be citable via a digital object identifier (DOI) number. The DOI 
for your paper will be 10.1038/nature12531. Once the paper is published 
electronically, the DOI can be used to retrieve the abstract and full 
text from the /Nature/ web site (abstracts are available to everyone, 
full text only to subscribers) by adding it to the following URL: 
http://dx.doi.org/ .
On the Tuesday before publication, /Nature/ distributes a press release 
highlighting papers of general interest. Journalists are given the name 
of the author(s) to contact, together with phone numbers and e-mail 
addresses. Journalists are also given online access not only to the 
papers on the press release but to all the papers due to appear in that 
issue. This means that your work could well receive media interest even 
if not featured on the press release, so it would be helpful if you (as 
corresponding author, we would, as a matter of course, put your name and 
affiliation on our press release as a contact, and attribute the work to 
you plus colleagues, so please let me know if this would not be 
appropriate) or a colleague could be available to answer any inquiries 
in the days leading up to publication.
You are free to discuss your paper with the media, but we ask you to do 
this no more than five days before the publication date, and to ensure 
that /Nature's/ embargo conditions are understood by journalists and 
others. /Nature/ reserves the right to halt the publication of a paper 
if these conditions are broken. Journalists are permitted to show papers 
to independent specialists a few days in advance of publication, under 
embargo conditions, solely for the purpose of commenting on the work 
described.
Wire services stories must always carry the embargo time at the head of 
each item, and may not be sent out more than 24 hours before that time.
Journalists should credit /Nature/ as the source of stories covered.
If you need further clarification about anything related to publicity, 
please contact one of the /Nature/ offices, as indicated below:
/For North America and Canada/
Neda Afsarmanesh (/Nature/, New York)
Tel: +1 212 726 9231; E-mail: n.afsarmanesh(a)us.nature.com 
<mailto:n.afsarmanesh@us.nature.com>
/For Japan, Korea, China, Singapore and Taiwan/
Eiji Matsuda (/Nature/, Tokyo)
Tel: +81 3 3267 8751; E-mail: e.matsuda(a)natureasia.com 
<mailto:e.matsuda@natureasia.com>
/For the UK/
Rebecca Walton (/Nature/, London)
Tel: +44 20 7843 4502; E-mail: r.walton(a)nature.com 
<mailto:r.walton@nature.com>
Rachel Twinn (/Nature/, London)
Tel: +44 20 7843 4658; E-mail: r.twinn(a)nature.com 
<mailto:r.twinn@nature.com>
If you are reporting sequence or structural data with an accession code 
for a public database, we request you to set the release into the public 
domain upon receipt of this letter. This will allow our editors to test 
the link from the journal website to the database in readiness for the 
date of publication of your article. For authors reporting protein 
structures, release of the coordinates now will also allow us to set up 
a three-dimensional view window within the online version of the article.
For any queries concerning proofs or corrections, please contact the 
Editorial Production department in London.
You and your coauthors, or your institutions, can also order copies of 
the issue of /Nature/ containing your article: please contact 
g.painter(a)nature.com <mailto:g.painter@nature.com>, stating the 
publication reference and the number of copies required.
If you and your coauthors are not subscribers to /Nature/ and would like 
to subscribe, please contact subscriptions(a)nature.com and ask for 
details of special prices for published /Nature/ authors.
On /24/713 10:49 AM, Tuuli Lappalainen wrote:
  Dear all,
 It is my great pleasure to tell you that the Geuvadis RNAseq paper has 
 been accepted in Nature!
 Needless to say, I'm extremely happy to finally be at this point, and 
 to be able to thank all of you for your contributions. We wouldn't be 
 here without the hard work from all of you, the huge pool of 
 scientific expertise and insight, and the collaborative spirit that 
 we've had in this project. Please pass my thanks also to technicians 
 and other members of your lab who contributed to this work.
 It was a really enjoyable experience to work with all of you, and I 
 hope that this will inspire many other collaborations amongst us. I 
 had a lot of fun and I hope you did too! But the most important thing 
 is that I think we can all be proud of the outcome. It's a great paper 
 and a great data set that make an important contribution to the field.
 We're now going through some final formatting edits, and we'll be in 
 touch about press releases, publication and embargo dates, etc. when 
 we know more. Feel free to share the news with close colleagues, but 
 please don't advertise this yet in the public domain such as social 
 media. The companions papers are in a good shape too: we're waiting 
 for the final confirmation of the acceptance of the QC paper in Nature 
 Biotechnology so more good news will follow, and the splicing paper is 
 under review in Genome Research.
 best regards,
 Tuuli
 PS. Please note that my University of Geneva email address will not 
 work for much longer (in case you didn't know, I'm spending this year 
 at Stanford). Please use tuuli.e.lappalainen(a)gmail.com for future 
 correspondence.
 
-- 
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA